CMR Surgical has appointed Daniel Moore as the new non-executive chair of its board of directors. With over three decades of experience in the medical technology industry, Moore is expected to further the company’s global strategy. This move aims to capitalize on his extensive background to enhance the reach and application of CMR’s flagship product, the Versius surgical robot.
Extensive Industry Experience
Previously, Daniel Moore held senior executive roles at Boston Scientific for nearly two decades. His tenure included positions such as president of inter-continental and distribution management. Moore’s recent role as chair of the board at LivaNova, along with his significant board-level executive experience with Brainscope, GI Dynamics, and the Medical Device Manufacturers Association, underscores his robust leadership capacity.
Strategic Vision for Versius
CMR Surgical expects Moore to drive the company’s growth strategy, focusing on expanding the Versius surgical robot’s presence in hospitals globally. CEO Supratim Bose emphasized Moore’s sector experience and leadership as invaluable assets.
“The surgical robotics sector is one of the most exciting in the medtech space, and Versius is a truly differentiated technology with many large untapped markets yet to be reached, and more patients to be served,”
said Moore.
Versius, known for its collaborative arms and bedside units, is designed for minimal access surgery, providing surgeons with the ability to reach critical areas such as the lungs, thymus, and esophagus. The system’s flexibility in port placement is tailored to individual patient needs, enhancing its utility in various surgical procedures.
Earlier reports about CMR Surgical indicated a steady focus on innovation and expansion within the surgical robotics market. The introduction of the vLimeLite, an integrated fluorescence imaging system earlier this year, exemplifies CMR’s commitment to advancing surgical technology. This system aids in visual assessments, offering surgeons enhanced capabilities for assessing blood flow and tissue perfusion, marking a significant step for the Versius Plus surgical robot.
In contrast, past developments were centered on achieving CE-marking for Versius Plus, making it the first surgical robot with integrated ICG (Indocyanine green) visualization capabilities. This milestone was part of a series of planned product releases aimed at strengthening CMR Surgical’s portfolio. The company’s efforts reflect a continuous drive to innovate and address the evolving needs of surgical practices worldwide.
CMR Surgical’s appointment of Daniel Moore highlights the company’s strategic intent to leverage seasoned leadership to further its market expansion. Moore’s experience is anticipated to guide the company’s vision in making Versius a prominent tool in minimal access surgeries. The ongoing advancements in imaging technology and the broadening of Versius’s applications indicate a sustained focus on comprehensive surgical solutions.
